The 2nd edition of FT US Pharma and Biotech Summit will provide a fresh perspective on the crucial issues impacting the pharma and biotech industries today. Senior industry leaders will share their insights, ideas and expertise on topics such as the pharma pricing and politics, the future of gene editing, tracking China’s pharma growth market and the opportunities and challenges of unconventional partnerships and collaborations across the new healthcare landscape.
FT US Pharma and Biotech Summit 2020
Pharma in the Age of Value and Affordability
Verily Life Sciences
With The Support Of
Global Clinical Research Partner
What attendees had to say about their 2019 experience
“This is a must-attend meeting for the healthcare industry. A thoughtfully curated agenda with industry leaders, emerging disruptors, patients and regulators makes this one of the top health events of the year.”
“The sessions highlighted the complexities that we have in the US healthcare system and the various viewpoints that we should all consider.”
“By far the most interesting summit to date. Basically stayed on topic and highlighted different views and perspectives effectively...”
Agenda - 14th May
9:00amOpening Remarks from the Chair
9:05amKeynote Address/ Interview
9:20amPanel: Pharma Pricing and Politics: From Rhetoric to Action?
The issue of rising drug prices remains front and centre of the political debate in the 2020 election year. A host of proposals have been put forward in recent months by the Senate Finance Committee, House Democrats and the White House to hold the pharma industry ‘accountable for its actions’. If some of the more hard-hitting measures come to light, the implications for the underlying economic model of the industry are potentially profound.
- What is the good, the bad and the ugly of the multitude of proposed reforms on the table? What are the proposals which could have a meaningful impact on drug prices?
- How are value-based pricing deals evolving and what impact could they potentially have on drug pricing?
- Are subscription models the way ahead for paying for one-time cures?
- Should patent reforms and attempts to address ‘evergreening’ and ‘patent thickets’ play a bigger role of the debate?
Peter Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
Terry Wilcox, Co-Founder and Executive Director, Patients Rising
Tom Fezza, Partner Life Sciences and Health Care Strategy Advisor, Deloitte
10:10amKeynote Interview/ Address
Alexander Hardy, CEO, Genentech
10:25amPanel: Mission Critical: Unlocking the Potential of Real-World Evidence ( RWE) / Real-World Data (RWD)
Real-World Evidence (RWE) is increasing in use and importance across the pharma and broader healthcare industry. Key drivers include the growing willingness to include RWE in regulatory decision-making, the extension of value-based pricing, as well as a mounting awareness of the strategic benefits RWE can bring in terms speedier and more efficient drug development, enhanced patient engagement and competitive edge in an ever more value driven, personalized healthcare system. Yet many barriers - both internal and external - exist before the full potential of RWE/RWD can realised.
- As the landscape for RWE continues to evolve, what are the implications for current infrastructure, governance, operating models, people and processes of pharma companies?
- What are the learnings and insights of market leaders who have developed end-to-end RWE /RWD capabilities?
- How is the data landscape evolving?
Susan Shiff, Senior Vice President and Head of Center for Observational and Real-World Evidence (CORE), Merck
Bernard Hamelin, Global Head of Medical Evidence Generation, Sanofi
11:05amNetworking Coffee Break
11:25amKeynote Address/ Interview
Jessica Mega, Chief Medical and Scientific Officer, Verily Life Sciences
11:40amBridging a Pharma-Digital Divide? Unconventional Partnerships and Collaborations in Pharma
As pharma companies navigate the new world of digital and value, they are working in close partnerships with players from the world of big tech and big data. Among the many benefits, these relationships allow pharma companies to leverage expertise and talent, build closer relationships with patients and gain a foothold in the fast-growing business of digiceuticals and AI-driven products and services. Yet it is often remarked that an unspoken divide separates the ‘parallel worlds’ of pharma and tech, preventing closer alignment and realizing the full potential that such partnerships can offer. The ‘glacial pace of decision-making’ and siloed world of in pharma is often contrasted with the more ‘agile and open’ world of tech.
- How real is the ‘cultural divide’ between pharma and data companies? What have been the experiences of such partnership to date? How synergistic are the relationships?
- How are pharma companies and their digital partners navigating challenges of IP, data rights, sharing and ownership and attributing value in such joint endeavours? How are partnership models evolving?
- How vital are partnerships: could pharma ‘go it alone’ on AI and digital therapeutics?
Daphne Koller, CEO and Founder, Insitro
Ofer Leidner, President and Co-Founder, Happify Health
Moderator: Mike DeLone, Principal, US Life Sciences Sector Leader, Deloitte
12:20pmKeynote Address/ Interview
William Lewis, Chairman and CEO, Insmed
2:05pmPanel: New Approaches for a New Age in Mental Health
Over 46 million Americans suffer from mental illness, yet difficulties experienced in gaining access to treatment specialists and a dearth of new psychiatric drugs has left patients with ever more limited treatment options. The cost and complexity of research in the field of mental illness has seen the withdrawal of big pharma from the field of psychiatric drug research over the past decades. Yet new research in the field of genomics and mental health and in emerging areas to include immunemodality drugs, psychedelics and beyond, as well as new efforts to better understand the biology of the brain and mental illness hold the promise of new drugs in the future. Meanwhile, a new wave of apps and other digital interventions are rapidly changing the way mental health care is delivered, extending delivery beyond pills and traditional, in-person sessions to offer around-the-clock support from remote physicians or tech-driven tools that reach the patient wherever they are. Healthcare providers and pharma companies alike are looking increasingly to provide digital mental health offerings, often in partnership with start-ups.
- What might be the next leap forward in psychiatric pharmacology?
- What is the potential for genomics in mental health?
- What are the advances in our understanding of biology of the brain and mental health which hold the promise for new drugs?
- What is the potential and the challenges (e.g dealing with high-risk scenarios) with the new generation of digital apps and treatments?
Oren Frank, Co-Founder and CEO, Talkspace
Husseini Manji, Global Therapeutic Head for Neuroscience, Janssen Research & Development
2:35pmInnovation Showcase/ Breakthrough Science: Beyond Opioids - Next Frontiers in Pain Medicine and Management
A contributing factor to the opioid crisis which has paralysed America and is now being felt in a growing number of countries is the absence of effective alternatives to pain modification and management. Despite current therapeutics and interventions, pain continues to pose a significant burden to patients and the healthcare system on a global scale. The number of adults living with chronic pain in the United States annually exceeds those living with cancer, diabetes and heart disease combined, and approximately one quarter of these people endure severe pain on a daily basis. Here we highlight one of the emerging innovations in alternative, non-opioid pain medicines and therapies and review the market potential.
Richard Hanbury, Founder, Sana Health
3:00pmNetworking Coffee Break
3:20pmPanel: Leader or Follower? Tracking China's Pharma Growth
China is stepping up its investment in life sciences and is aiming to take a lead in drug development, AI, gene editing and gene therapies. It is also now the second largest pharmaceuticals market in the world and is set to be the first within 7-10 years. Recent moves by the industry regulator are paving the way for faster drug approvals and greater access for patients to advanced therapies. Meanwhile, China is embracing digital at a pace which eclipses the efforts in most other countries, and lacking the burden of legacy primary health care systems, is creating innovate new treatment and service models. Having a strategic presence in China is now as paramount. In the immediate term, however, a looming trade war and the impacts of restrictive foreign investment rules in the form of CIFUS are expected to play a moderating role on the potential for closer US-China life science collaboration. What is the true potential of innovative drug development in China? If China’s innovator drugs can undercut US prices, should the global industry be on notice?
Hui Wu, Venture Partner, Chareon Pokphand Asset Management
4:10pmThe Future of Cell and Gene Therapies
The excitement surrounding the potential of cell and gene therapies continues with important new developments underway. After developing the first gene therapies for rare diseases, biotech companies are seeking to extend gene treatments to common illnesses affecting millions of people, providing new competition for big pharma in the process. Meanwhile, with the advent if the first human in-body gene editing, we are entering a new stage in the gene editing revolution that could lead to more diseases being treated or cured with this technology. However, many questions remain unanswered.
- The new therapies look transformational, but will they be commercially successful for pharma given the manufacturing, administration, reimbursement and other complexities?
- How can we industrialize personalisation to ensure sustainable patient access to advanced therapies?
- How could the ‘engineering’-based approach of gene editing potentially transform the business of pharma?
- Can the safety and ethical concerns surrounding gene editing be addressed? Where do we draw the line between risk and opportunity?
David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer, Vertex Pharmaceuticals
Sandy Macrae, President and Chief Executive Officer, Sangama Therapeutics
Natalie Kofler, Founder, Editing Nature
5:00pmClosing Remarks from the FT Chair
Dr Peter Bach is a physician, epidemiologist, writer, and recognized expert in healthcare policy whose work has been regularly featured in major scientific and lay press outlets such as the NEJM, JAMA, and the New York Times. He is the Director, and currently holds the titles of Member in the Department of Epidemiology and Biostatistics and Attending Physician in the Department of Medicine at Memorial Sloan Kettering. He has also been a Senior Scholar at the International Agency for Research on Cancer since 2008.
Dr Bach is a member of the Institute of Medicine’s Board on Health Care Services and National Cancer Policy Forum and the Committee on Performance Measurement of the National Committee on Quality Assurance; he is also the Chair of the Center for Medicare and Medicaid Services Technical Expert Panel, which works to develop quality measures for PPS-exempt cancer hospitals. He has been inducted into the American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He also serves on the Board of Advisors of the University of Michigan Cancer Center and on the World Economic Forum, and is a member of the Clinton Global Initiative. Previously, Dr Bach was a member of the Institute of Medicine’s Committee on Geographic Variations and the Chair of a multi-society evidence-based guideline development committee on lung cancer screening. He also served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006
Dr Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar.
Tom Fezza is a Principal in Deloitte’s Life Sciences Strategy practice based in New York. He has over 20 years of consulting experience working with life sciences and health care companies. His areas of expertise include strategic planning, growth, R&D and therapeutic area strategy development, as well as operating model redesign.
Mr Fezza’s experiences are diverse, and range from defining and evaluating new business models, enterprise growth strategies, and commercialization strategies to assessing the performance and value of R&D organizations. He has worked with senior pharmaceutical, biotech, and health tech start-up leadership to successfully define and implement transformational strategies.
Mr Fezza is a graduate of the United States Military Academy at West Point. He also holds an MBA from the Wharton School at the University of Pennsylvania.
Oren Frank is a Co-founder and the CEO of Talkspace, the leading online and mobile psychotherapy company that has made therapy accessible and affordable to people across the globe. In a day and age when mental health care is recognized as a global societal crisis, the effectiveness and
convenience Talkspace provides to those seeking to improve their mental health and well-being stands out. Under Oren’s leadership, Talkspace has so far helped more than 500,000 clients connect with licensed therapists — the vast majority of whom had no prior access. As an avid believer in the
power of innovation and technology to better society, Mr Frank founded Talkspace with his wife Roni in 2012, with the vision of “Therapy for all.” After experiencing the benefits of couples therapy earlier in their marriage, they launched Talkspace with the strong belief that mental health care is a moral
right, and everyone should have access to the support and value psychotherapy provides whenever the need or want arises.
Prior to Talkspace, Mr Frank was a successful senior marketing and advertising executive, mostly with McCann Erickson WorldWide, where he was recognized as a progressive creative strategist, and one of the leading voices in the new media-marketing world. Mr Frank maintains that Talkspace helps him redeem and repent for his years spent in advertising.
Susan Shiff joined Merck in 2014 as Senior Vice President and head of the CORE organization. CORE links together epidemiologists, health economists, access and reimbursement scientists, health services researchers and others involved in health policy research with the goal of leading global strategic value evidence generation and access strategy development to optimize reimbursement and patient outcomes across Merck’s portfolio.
Prior to joining Merck, Dr Shiff was the Global Vice President, Health Economics Research and Evidence Based Medicine at Teva. Prior to Teva, she spent seven years at Pfizer, including several years as Vice President in the areas of outcomes research, epidemiology, health economics, and access and pricing. She has also led the global risk management group and US HEOR group at Roche and spent four years at the US Centers for Disease Control and Prevention (CDC).
Dr Shiff received her PhD degree from UCLA, and an MBA degree from Cornell University. She currently serves on the Institute for Clinical and Economic Review (ICER), Advisory Board and Methods Sub-Committee; Health Technology Assessment International (HTAi), Policy Advisory Board; the Innovation and Value Initiative (IVI), Panel of Health Advisors, the Academy of Managed Care Pharmacy (AMCP) Foundation Board, and the New Jersey Symphony Orchestra, Board of Trustees, Education, and Development Committees. She is also a Non-Executive Director of Synthace Ltd. In 2016, Dr Shiff was named one of the top 15 women in Biopharma by FiercePharma.
Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York. Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.
Sarah Neville is Global Pharmaceuticals Editor of the Financial Times, a position she has held since 2016. She joined the Financial Times in 2001 and has held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and Public Policy Editor. She began her career on local and regional newspapers, eventually becoming Political Editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post.
Companies in attendance in 2019
Sanofi • FDA • Eisai • Bayer • AstraZeneca • Novartis Pharmaceuticals • Mylan • Otsuka • GlaxoSmithKline • Eli Lilly • Pfizer • National Pharmaceutical Council • Takeda • UCB • Janssen • Vitruvian Biomedical • Bristol Myers Squibb • BioMarin Pharmaceutical Inc • Aquestive Therapeutics • Johnson & Johnson • Ibex Biosciences • Bound Therapeutics LLC • Horizon Pharma • Spark Therapeutics • Celgene • Regeneron Pharmaceuticals • CONTINUUS Pharmaceuticals and many others.
The FT US Pharma & Biotech Summit will be attended by CEOs, CFOs, CTOs CIOs, Head of R&D, Chief Medical Officers, Chief Strategy Officers, Chief Digital Officers, Market Access and Pricing, Chief Business Officers and other senior-level executives in the following sectors:
- Pharmaceutical & Biotechnology Companies
- Pharmaceutical Wholesalers/PBMs
- Healthcare insurers and government payers
- Government healthcare departments and agencies
- IT, big data and analytics providers
- Medical Device Manufacturers
- Investment bankers, private equity and VCs
- Patient representatives and health-related NGOs
- Gain access to 250 executives and leaders from across the US pharmaceutical industry;
- Brand alignment with the FT and its unrivalled credibility;
- Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
- Benefit from sustained international visibility through our advertising and marketing campaigns
Head of Portfolio
- Gain insights into the healthcare reforms being proposed by US Presidential candidates and how they might affect pharma pricing and risk
- Hear how payer’ perspectives on value is evolving
- Discuss the challenges and opportunities of unconventional partnerships in pharma and the myth and reality of pharma’s digital divide
- Debate whether governments should play a bigger role in drug development as ROI diminishes, shortages increase and price of drugs continue to rise
- Get the inside story on whether China will be a leader or follower in life sciences as the county’s level of ambition and innovation increases
- Discover the latest development in gene editing and have your say on where we should draw the line between risk and opportunity
PRESENTED BY (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.
With the support of (1)
About Life Sciences and Health Care at Deloitte
Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
Global Clinical Research Partner (1)
ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.
ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.
With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 40 countries and has approximately 14,500 employees. For further information please visit www.iconplc.com Follow @iconplc on Twitter.